Title: PHARMACOLOGY OF MONOAMINE OXIDASE INHIBITORS
Abstract: Three different types of MAO inhibitors, i.e. hydrazine derivatives, phenylcyclopropylamine, and pargyline, are in clinical use. They cause a potent, long-lasting, irreversible inhibition of MAO and induce the following typical pharmacological effects on the central nervous system of animals: Increase of endogenous monoamines, such as 5-hydroxytryptamine and catecholamines. Enhancement of the monoamine increase and of the locomotor as well as the sympathetic stimulation due to administration of monoamines (e.g. tryptamine and tyramine) and their precursors (e.g. DOPA). Counteraction against the monoamine decrease induced by monoamine releasers (Rauwolfia alkaloids and benzoquinolizine derivatives) and antagonism or reversal of their sedative effect. These pharmacological actions as well as the psychostimulation in humans are probably connected with MAO inhibition. An increase of the free monoamines at the adrenergic receptors might be the biochemical correlate for the psychostimulant effect. These pharmacological actions as well as the psychostimulation in humans are probably connected with MAO inhibition. An increase of the free monoamines at the adrenergic receptors might be the biochemical correlate for the psychostimulant effect.
Publication Year: 1965
Publication Date: 1965-01-01
Language: en
Type: book-chapter
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot